Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shweta S Chavan

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2020
Genomic Landscape of Uterine Sarcomas Defined Through Prospective Clinical SequencingMartee L Hensley, Shweta S Chavan, David B Solit, et al.
Blood|September 20, 2014
Genome-wide scan identifies variant in 2q12.3 associated with risk for multiple myelomaStephen W Erickson, Vinay R Raj, Owen W Stephens, et al.
Iscience|October 29, 2021
MAPK pathway activation selectively inhibits ASCL1-driven small cell lung cancerRebecca Caeser, Christopher Hulton, Emily Costa, et al.
Nature Communications|January 2, 2025
A deep multiple instance learning framework improves microsatellite instability detection from tumor next generation sequencingJohn Ziegler, Jaclyn F Hechtman, Satshil Rana, et al.
Cell Reports|May 18, 2022
WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLCHirokazu Taniguchi, Rebecca Caeser, Shweta S Chavan, et al.
Blood|August 13, 2016
Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myelomaNiels Weinhold, Cody Ashby, Leo Rasche, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 29, 2016
The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in MyelomaCharlotte Pawlyn, Martin F Kaiser, Christoph Heuck, et al.
Cancer Research|November 24, 2021
Inhibition of XPO1 Sensitizes Small Cell Lung Cancer to First- and Second-Line ChemotherapyAlvaro Quintanal-Villalonga, Hirokazu Taniguchi, Yuan Hao, et al.
The Journal of Clinical Investigation|September 8, 2020
Germ cell tumors and associated hematologic malignancies evolve from a common shared precursorJustin Taylor, Mark Ta Donoghue, Caleb Ho, et al.
The Lancet. Oncology|May 22, 2020
First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trialYelena Y Janjigian, Steven B Maron, Walid K Chatila, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2020
Genomic Landscape of Uterine Sarcomas Defined Through Prospective Clinical SequencingMartee L Hensley, Shweta S Chavan, David B Solit, et al.
Blood|September 20, 2014
Genome-wide scan identifies variant in 2q12.3 associated with risk for multiple myelomaStephen W Erickson, Vinay R Raj, Owen W Stephens, et al.
Iscience|October 29, 2021
MAPK pathway activation selectively inhibits ASCL1-driven small cell lung cancerRebecca Caeser, Christopher Hulton, Emily Costa, et al.
Nature Communications|January 2, 2025
A deep multiple instance learning framework improves microsatellite instability detection from tumor next generation sequencingJohn Ziegler, Jaclyn F Hechtman, Satshil Rana, et al.
Cell Reports|May 18, 2022
WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLCHirokazu Taniguchi, Rebecca Caeser, Shweta S Chavan, et al.
Blood|August 13, 2016
Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myelomaNiels Weinhold, Cody Ashby, Leo Rasche, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 29, 2016
The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in MyelomaCharlotte Pawlyn, Martin F Kaiser, Christoph Heuck, et al.
Cancer Research|November 24, 2021
Inhibition of XPO1 Sensitizes Small Cell Lung Cancer to First- and Second-Line ChemotherapyAlvaro Quintanal-Villalonga, Hirokazu Taniguchi, Yuan Hao, et al.
The Journal of Clinical Investigation|September 8, 2020
Germ cell tumors and associated hematologic malignancies evolve from a common shared precursorJustin Taylor, Mark Ta Donoghue, Caleb Ho, et al.
The Lancet. Oncology|May 22, 2020
First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trialYelena Y Janjigian, Steven B Maron, Walid K Chatila, et al.
Pageof 3